Patents by Inventor Dan T. Stinchcomb

Dan T. Stinchcomb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220062375
    Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 3, 2022
    Applicants: TAKEDA VACCINES, INC., THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT
    Inventors: Dan T. STINCHCOMB, Claire KINNEY, Richard M. KINNEY, Jill A. LIVENGOOD
  • Patent number: 11192941
    Abstract: This disclosure provides a multimeric human immunodeficiency virus (HIV) protein binding molecule, e.g., an dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HIV antigen binding domain. Also provided are compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: December 7, 2021
    Assignee: IGM Biosciences, Inc.
    Inventors: Bruce Alan Keyt, Dan T. Stinchcomb, Ole A. Olsen
  • Patent number: 10898565
    Abstract: Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: January 26, 2021
    Assignees: Takeda Vaccines, Inc., The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Jill A. Livengood, Claire Kinney, Timothy D. Powell, Dan T. Stinchcomb, Jorge Osorio
  • Publication number: 20200377577
    Abstract: This disclosure provides a multimeric human immunodeficiency virus (HIV) protein binding molecule, e.g., an dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HIV antigen binding domain. Also provided are compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.
    Type: Application
    Filed: January 7, 2020
    Publication date: December 3, 2020
    Inventors: Bruce Alan Keyt, Dan T. Stinchcomb, Ole A. Olsen
  • Patent number: 10806781
    Abstract: Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: October 20, 2020
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Jill A. Livengood, Laszlo Varga
  • Publication number: 20200061151
    Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
    Type: Application
    Filed: September 5, 2019
    Publication date: February 27, 2020
    Inventors: Dan T. STINCHCOMB, Claire KINNEY, Richard M. KINNEY, Jill A. LIVENGOOD
  • Patent number: 10570191
    Abstract: This disclosure provides a multimeric human immunodeficiency virus (HIV) protein binding molecule, e.g., an dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HIV antigen binding domain. Also provided are compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: February 25, 2020
    Assignee: IGM Biosciences, Inc.
    Inventors: Bruce Alan Keyt, Dan T. Stinchcomb, Ole A. Olsen
  • Patent number: 10449231
    Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: October 22, 2019
    Assignees: TAKEDA VACCINES, INC., The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Dan T. Stinchcomb, Claire Kinney, Richard M. Kinney, Jill A. Livengood
  • Publication number: 20190151433
    Abstract: Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.
    Type: Application
    Filed: June 1, 2018
    Publication date: May 23, 2019
    Inventors: Jill A. Livengood, Claire Kinney, Timothy D. Powell, Dan T. Stinchcomb, Jorge Osorio
  • Publication number: 20190134182
    Abstract: Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.
    Type: Application
    Filed: October 12, 2018
    Publication date: May 9, 2019
    Inventors: Dan T. Stinchcomb, Jill A. Livengood, Laszlo Varga
  • Patent number: 10137186
    Abstract: Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: November 27, 2018
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Jill A. Livengood, Laszlo Varga
  • Publication number: 20180251737
    Abstract: Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally related to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.
    Type: Application
    Filed: December 28, 2017
    Publication date: September 6, 2018
    Inventors: Dan T. Stinchcomb, Jill A. Livengood, O'Neil Wiggan, Richard Kinney, Jorge Osorio
  • Patent number: 10052374
    Abstract: Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: August 21, 2018
    Assignees: Takeda Vaccines, Inc., The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Jill A. Livengood, Claire Kinney, Timothy D. Powell, Dan T. Stinchcomb, Jorge Osorio
  • Publication number: 20180228887
    Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject using trivalent dengue virus vaccine compositions. In some embodiments, more than one vaccine composition may be administered to a subject in different anatomical locations in order to induce a rapid response to at least three of four dengue virus serotypes. In certain embodiments, administration of a trivalent dengue virus vaccine composition can be combined with administration of a monovalent dengue virus vaccine composition.
    Type: Application
    Filed: December 15, 2017
    Publication date: August 16, 2018
    Inventors: Dan T. Stinchcomb, Joseph N. Brewoo, Jorge E. Osorio, Charalambos D. Partidos
  • Patent number: 10010600
    Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against dengue viruses. In some embodiments, vaccine compositions may be administered by intradermal introduction. In certain embodiments, intradermal introduction in a subject of a vaccine against dengue virus may include one or more intradermal boosts after initial vaccination. Other embodiments include intradermal injection of a vaccine composition against dengue virus wherein the composition provides protection against two or more of DEN-1, DEN-2, DEN-3 and DEN-4.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: July 3, 2018
    Assignee: TAKEDA VACCINES, INC.
    Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Charalambos D. Partidos, Joseph N. Brewoo
  • Publication number: 20180118816
    Abstract: This disclosure provides a multimeric human immunodeficiency virus (HIV) protein binding molecule, e.g., an dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HIV antigen binding domain. Also provided are compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.
    Type: Application
    Filed: April 15, 2016
    Publication date: May 3, 2018
    Inventors: Bruce Keyt, Dan T. Stinchcomb, Ole A. Olsen
  • Patent number: 9890362
    Abstract: Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally relate to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: February 13, 2018
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T Stinchcomb, Jill A. Livengood, O'Neil Wiggan, Richard Kinney, Jorge Osorio
  • Patent number: 9878031
    Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject using trivalent dengue virus vaccine compositions. In some embodiments, more than one vaccine composition may be administered to a subject in different anatomical locations in order to induce a rapid response to at least three of four dengue virus serotypes. In certain embodiments, administration of a trivalent dengue virus vaccine composition can be combined with administration of a monovalent dengue virus vaccine composition.
    Type: Grant
    Filed: December 7, 2013
    Date of Patent: January 30, 2018
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Joseph N. Brewoo, Jorge E. Osorio, Charalambos D. Partidos
  • Publication number: 20180008691
    Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against all dengue virus serotypes. In some embodiments, multiple vaccine compositions may be administered to a subject in different anatomical locations in order to induce a rapid response to all dengue virus serotypes. In certain embodiments, administration of two or more vaccine compositions to a subject against all dengue virus serotypes may include two or more routes of administration.
    Type: Application
    Filed: June 16, 2017
    Publication date: January 11, 2018
    Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Charalambos D. Partidos, Joseph N. Brewoo
  • Publication number: 20170290884
    Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
    Type: Application
    Filed: April 20, 2017
    Publication date: October 12, 2017
    Inventors: Dan T. Stinchcomb, Claire Kinney, Richard M. Kinney, Jill A. Livengood